Shares of VIA Pharmaceuticals Inc. jumped 45 percent Friday after the company presented a Phase II subset analysis showing that VIA-2291 reduced unstable coronary plaques in patients with acute coronary syndrome. (BioWorld Today)

At last week's 44th annual meeting of the European Association for the Study of the Liver (EASL), all eyes were on preliminary data from INFORM-1, the first study to combine two direct-acting antivirals for hepatitis C. (BioWorld Financial Watch)